62. Cancer vaccines and the future of immunotherapy.
作者: Orrin Pail.;Matthew J Lin.;Theodora Anagnostou.;Brian D Brown.;Joshua D Brody.
来源: Lancet. 2025年
Vaccines have had a major impact on the control of infectious disease, most recently by helping to combat the COVID-19 pandemic. Prophylactic cancer vaccines have prevented several malignancies by protecting against cancer-causing pathogens. By contrast, therapeutic vaccines training the immune system to eliminate established tumours are now showing real promise in clinical settings. In the adjuvant setting, vaccines against melanoma and pancreatic cancer appear to be reducing minimal residual disease and relapse. In the macrometastatic setting, in-situ vaccines have induced systemic regressions in advanced-stage lung and breast cancers and lymphomas. More effective cancer vaccines are being developed through having a deeper understanding of crucial cellular factors in tumour immunology, the incorporation of newer vaccine components to effectively mobilise and activate cells, the use of omics and artificial intelligence in vaccine design, and addition of immune checkpoint blockade. In this Viewpoint, we analyse cancer vaccine trials, the strengths and limitations of different vaccine approaches, and we discuss how the next generation of cancer vaccines can help improve patient outcomes and quality of life.
67. Surgery versus corticosteroid injection for carpal tunnel syndrome (DISTRICTS): an open-label, multicentre, randomised controlled trial.
作者: Wijnand A C Palmbergen.;Roy Beekman.;A Marijne Heeren.;Bart F L van Nuenen.;Tim W H Alleman.;Esther Verstraete.;Korné Jellema.;Wim I M Verhagen.;Leo H Visser.;Godard C W de Ruiter.;Diederik van de Beek.;Corianne A J M de Borgie.;Johannes A Bogaards.;Rob M A de Bie.;Camiel Verhamme.; .
来源: Lancet. 2025年405卷10495期2153-2163页
Surgery and corticosteroid injections are established treatments for carpal tunnel syndrome, but the optimal treatment strategy remains unclear. This study aimed to compare starting treatment with surgery versus starting with a corticosteroid injection.
68. Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial.
作者: Sheela Rao.;Emmanuelle Samalin-Scalzi.;Ludovic Evesque.;Meher Ben Abdelghani.;Federica Morano.;Amitesh Roy.;Laetitia Dahan.;Stefano Tamberi.;Amandeep Singh Dhadda.;Mark P Saunders.;Nathalie Casanova.;Rosine Guimbaud.;Astrid Lievre.;Joan Maurel.;Marwan Fakih.;Chuan Tian.;Jill Harrison.;Mark M Jones.;Mark Cornfeld.;Jean-Philippe Spano.;Pauline Rochefort.; .
来源: Lancet. 2025年405卷10495期2144-2152页
Retifanlimab has activity in programmed death ligand 1-positive advanced squamous cell anal carcinoma (SCAC) that has progressed on platinum chemotherapy. We aimed to prospectively assess the benefit of adding retifanlimab to initial carboplatin-paclitaxel for this disease.
70. Beyond deficit models in early childhood development science.
作者: Gabriel Scheidecker.;Tatek Abebe.;Seye Abimbola.;Nandita Chaudhary.;Willem E Frankenhuis.;Heidi Keller.;Yuko Munakata.;Bolajoko O Olusanya.;Dandara de Oliveira Ramos.;Muneera A Rasheed.
来源: Lancet. 2025年405卷10495期2127页 76. Human reproduction in crisis: causes unknown.
作者: Niels E Skakkebaek.;Lærke Priskorn.;Rune Lindahl-Jacobsen.;Anna-Maria Andersson.;David M Kristensen.;Astrid Linnea Beck.;Lise Aksglaede.;Margit Bistrup Fischer.;Luiz R Franca.;Anders Juul.
来源: Lancet. 2025年405卷10495期2121-2122页 |